Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:PRM
NYSE:PRMChemicals

Assessing Perimeter Solutions (PRM) Valuation After UBS Downgrade And Medical Manufacturing Technologies Deal

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...
NasdaqGS:WLTH
NasdaqGS:WLTHCapital Markets

Wealthfront (WLTH) Margin Compression Challenges Bullish Growth Narratives After Q3 2026 Results

Wealthfront (WLTH) just posted its Q3 2026 numbers, with revenue of US$93.2 million, basic EPS of US$0.72 and trailing twelve month EPS of US$3.04 setting the backdrop for the quarter. The company has seen revenue move from US$80.3 million in Q3 2025 to US$93.2 million in Q3 2026, while quarterly EPS has shifted from US$0.77 to US$0.72 over the same period, against trailing twelve month revenue of US$351.5 million. With a current net profit margin of 35.2% versus 57.7% a year ago, this update...
ASX:TEA
ASX:TEAConstruction

Is Tasmea’s Updated Share Plan Quietly Redefining Governance Priorities at Tasmea (ASX:TEA)?

Tasmea recently updated its share incentive program, outlining a refreshed equity-based reward structure aimed at strengthening governance transparency and aligning employee interests with shareholders. This move highlights how equity-based compensation can support workforce cohesion while keeping the company’s overall capital structure broadly consistent within Australia’s listed market framework. We’ll now examine how Tasmea’s renewed focus on governance transparency through its share...
ASX:SUL
ASX:SULSpecialty Retail

How Record H1 FY26 Sales and Lower Profit Guidance At Super Retail Group (ASX:SUL) Has Changed Its Investment Story

Super Retail Group recently reported record first-half FY26 sales of A$2.20 billion, with total sales up 4.2% and like-for-like sales growing 2.5%, but guided to a lower normalised profit before tax of A$172 million to A$175 million versus the prior period. The result highlights a tension between strong trading momentum and profitability, as elevated discounting, margin pressure at rebel, and duplication costs from new systems and distribution infrastructure weighed on earnings despite a...
NasdaqCM:VFF
NasdaqCM:VFFFood

Assessing Village Farms International (NasdaqCM:VFF) Valuation After New Dutch Cannabis Product Launch

Village Farms International (VFF) has drawn fresh attention after its Leli Holland unit rolled out ten new cannabis products into the regulated Dutch market, including the country’s first licensed blunt and several tailored spliff formats. See our latest analysis for Village Farms International. At a share price of $3.50, Village Farms International has seen a 30 day share price return decline of 14.22% and a year to date share price return decline of 5.15%. Its 1 year total shareholder...
NYSE:DDD
NYSE:DDDMachinery

Is 3D Systems (DDD) Quietly Recasting Its Investment Story Around Mission-Critical 3D Printing?

3D Systems recently presented at the 28th Annual Needham Growth Conference while highlighting expanded Aerospace & Defense operations, new FDA clearance for its VSP Orthopedics platform, and balance-sheet strengthening through equity-funded debt reduction. Together, the push into defense-focused manufacturing, broader orthopedic indications, and efforts to reinforce the capital structure underscore how the company is repositioning around mission-critical, higher-value applications. We’ll now...
SGX:A50
SGX:A50Healthcare

Will Thomson Medical Group’s (SGX:A50) New Chairman Reframe Its Capital-Intensive Expansion Narrative?

Thomson Medical Group Limited has announced that Mr. Tong Kooi Ong will become Independent and Non-Executive Chairman on February 1, 2026, succeeding Mr. Ng Ser Miang, who steps down on January 31, 2026, along with changes to key board committee roles. The appointment brings in a veteran entrepreneur with deep experience in property-related, capital-intensive projects across Southeast Asia, aligning with Thomson Medical Group’s ambitions for large-scale developments such as the Johor Bay...
NYSE:CXW
NYSE:CXWCommercial Services

Is CoreCivic (CXW) Attractive After Recent Share Price Pullback And Valuation Checks

If you are wondering whether CoreCivic’s share price still offers value at around US$19.94, you are not alone. This article focuses squarely on what that price could mean for investors. The stock has returned 5.2% over the last 7 days, 5.5% over the last 30 days, 4.8% year to date, while its 1 year return of a 10.7% decline sits against a 76.8% return over 3 years and 173.9% over 5 years. Recent headlines around CoreCivic have continued to keep the company in focus, with investors weighing...
NasdaqGS:CRNX
NasdaqGS:CRNXPharmaceuticals

Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates

Crinetics Pharmaceuticals recently completed a US$350.14 million follow-on common stock offering after reporting over US$5 million in preliminary fourth-quarter 2025 PALSONIFY revenue and positive Phase 2 atumelnant data in classic congenital adrenal hyperplasia. Together, these updates highlight early commercial traction for PALSONIFY and clinical progress for atumelnant, while the equity raise may bolster Crinetics’ ability to fund further development and commercialization. We’ll now...
NYSE:DAL
NYSE:DALAirlines

Delta Air Lines Q4 Net Margin Boost From One Off Gain Tests Bullish Profitability Narrative

Delta Air Lines (DAL) has just wrapped up FY 2025 with Q4 revenue of US$16.0b and basic EPS of US$1.88, alongside net income excluding extra items of US$1,219m. Over the past year, revenue on a trailing twelve month basis moved from US$61.6b with EPS of US$5.39 to US$63.4b with EPS of US$7.72, while trailing net income excluding extra items rose from US$3,457m to US$5,005m. For investors, the current earnings outline a picture of firmer margins and profitability that now need to be weighed...